Aladdin Healthcare Technologies : Annual Report of the Group 2020

Annual Report 2020

Aladdin Healthcare Technologies SE

Content

Foreword by the Managing Director

The Share

Equity Research

Investor Relations

Consolidated Financial Statements at 31 December 2020

Combined Management and Group Management Report for the year 2020 ESEF Explanation

Independent Auditor's Report

Attestation by the legal Representatives

Foreword by the Managing Director

Dear Shareholder,

With the publication of the report for the financial year of 2020, I would like to take this opportunity to update you on both the development and status of the business. We have had a period of transition in the financial year 2020, which has resulted in moving away from old partnerships and developing new commercial relationships and technologies.

Highlights of the current financial year include:

• The Group has experienced a challenging year in terms of funding. We announced a public offering of new shares for 3 March 2020. However, the Board decided to postpone the public offering until later in the financial year due to the negative impact of the COVID 19 pandemic on global financial markets. As a result, the Group will have to rely on funding from existing shareholders in 2020 and 2021, Going forward, the Group's funding and research and development projects will be secured through external investment. If third-party funding is not yet available, the Group's financing will continue to be secured through shareholders.
• We have developed a prototype for the early diagnosis of Alzheimer's disease based on blood test results. The AI diagnosis is based on a non-invasive blood test that can provide an instant diagnosis for health screening of several age-related diseases. We have achieved high accuracy in diagnosing Alzheimer's disease with our AI model based on blood test results. These diagnoses are now being validated through our extensive and industry-leading hospital network.
• The company has appointed Professor David C. Rubinsztein as Chief Scientific Advisor. David C. Rubinsztein is Deputy Director of the Cambridge Institute of Medical Research, Professor of Molecular Neurogenetics at the University of Cambridge and Professor at the UK Dementia Research Institute. His research interests are in autophagy and neurodegeneration. He is a Fellow of the Royal Society and the Academy of Medical Sciences. David is a highly cited researcher by Clarivate Analytics and Thomson Reuters. He has published more than 390 papers, including studies in well-known international journals such as Nature and Cell, with more than 75,000 Google Scholar citations.
• Aladdin has developed a Health Risk Assessment Tool (HRA) as a web and mobile application to manage COVID-19 risk assessment for global use. The HRA tool combines both artificial intelligence (AI) and augmented reality (AR) to open up new possibilities in COVID-19 risk management for businesses and individuals. Aladdin will initially roll out the technology in India. Specifically, the AI application provides users with a real-time risk assessment of individuals infected with the coronavirus. In addition, the application can take further steps in their treatment. For example, it shows whether doctors are available for a video consultation and the

nearest available hospital for treatment. At the same time, the AI suggests suitable further treatment measures and gives lifestyle tips.

• The Company had resolved on 3 March 2020 that it would carry out the capital increase to the extent that new shares were subscribed for in the subscription offer (including oversubscriptions by existing shareholders). To this extent, the Company issued a total of 8,238 new shares at a price of EUR 5,90 and the share capital of the Company was increased by EUR 8,238.00 from the current EUR 11,450,000.00 to EUR 11,458,238.
• In July 2020, Aladdin Ltd. UK established Aladdin Healthcare Technologies China Ltd. in the PRC (Aladdin China) together with Mr. Jiang Yinghui. Aladdin holds a 51% interest in the (subsidiary) company. The purpose of this subsidiary is to outsource part of our data science software development to China. In this way, the company can access the significant data science potential in the Chinese region at a lower cost, effectively saving capital.
• In November 2020 Aladdin successfully validated its deep learning algorithms - Pre-trainedSelf-Attentive Message Passing Neural Network - for drug discovery. The European Journal of Medicinal Chemistry, a global impactful journal about medical chemistry, accepted and published Aladdin´s and its partners´ research paper on the discovery of highly potent anti- osteoporosis natural products by means of deep learning algorithms. The research paper has been partly published at www.sciencedirect.com.

We have built an AI and data science development team from Europe, China and India. These individuals bring very good healthcare networks and partners that give Aladdin credibility in the healthcare industry.

Berlin,

Wade Menpes-Smith

Managing Director

The Share

REGISTERED CAPITAL	EUR 11,458,238
NUMBER OF SHARES	11,458,238 no-par value bearer shares
	Düsseldorf (Regulated Market), Xetra, Frankfurt,
STOCK EXCHANGE	Berlin, Munich
MARKET SEGMENT	Regulated market
WKN	A12ULL
ISIN	DE000A12ULL2
TICKER SYMBOL	NMI
ACCOUNTING STANDARD	IFRS
FINANCIAL YEAR	31 December 2020

The share price has performed poorly over the financial year 2020. Global share prices dropped in March after the announcement of lockdowns across multiple nations. However, the company's share continued to decrease throughout the year. Management believes this is due to postponement of the company's public offering.

Equity Research

At present, Aladdin Healthcare Technologies SE was not covered by research companies in 2020 as the company did not have a budget to provide Investor Research, we continue to focus our efforts on development and will engage equity research when management believes we have a sufficient budget to do so.